Multiple Sclerosis Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older who have been treated with ocrelizumab for a relapsing form of Multiple Sclerosis, following the approved treatment schedule, for at least 18 months.
- People whose IgG levels (a type of immune protein in the blood) have been measured as lower than normal at least twice in a row, approximately six months apart, while receiving ocrelizumab treatment.
- People who have already switched, or are in the process of switching, from ocrelizumab to a different medication called ofatumumab, where that switch was decided independently of this study.
- People who agree to take part in the study.
- People who are able to provide a formal statement that they do not object to participating.
- People for whom the treating doctor expects a benefit from participation, based on the doctor's experience and the individual's characteristics.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose ocrelizumab doses were spaced more than 8 months apart at any point in the 18 months before switching medications.
- People who received immunoglobulin supplementation therapy (treatment to boost immune proteins) at any point in the 18 months before switching medications.
- People who are currently pregnant or planning to become pregnant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 06.33.38.32.60
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Slope of serum immunoglobulin G (IgG) levels during ocrelizumab treatment period (minimum 18 months); Slope of serum immunoglobulin G (IgG) levels during ofatumumab treatment period (24 months)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.